NovaScan FastPath surgical probe

Need : 

Improved methods of identifying ‘clean’ from cancerous tissue during breast surgery Existing methods Visual inspection by surgeon Tissue pathology (‘frozen sections’) Weaknesses Failure to detect 12-25% of cancer Repeat surgery rate of 20-40% Implications Inefficiency and increased cost to hospital & patient risk Need Dr. William Gregory wdguwm@aol.com 1

Impact/Opportunity : 

Reduce healthcare costs by decreasing number of repeat surgeries (~ $ 0.8 billion) Improve surgical efficiency throughput, reduce liability Reduce patient’s risk and improve outcomes. 10,000 centers world-wide perform breast cancer surgeries U.S. / International market $100 million+/yr Impact/Opportunity Dr. William Gregory wdguwm@aol.com 2 Aurora St Luke’s Hospital

NovaScan’s Real-Time Solution : 

NovaScan’s Real-Time Solution Dr. William Gregory wdguwm@aol.com 3 94% Sensitivity 83% Specificity Trialed at Aurora Hospitals 6 Issued Patents, 9 Pending WiSys/WARF is licensor

Team/Strategy : 

Team/Strategy Dr. William Gregory wdguwm@aol.com 4 CSO: William Gregory PhD (MIT), PE; 4 decade career in academe and industry Sec.-Treas. & Business Manager: Jack McClurkin, 30 years in manufacturing Staff & BOD: medical device developers (GE, Marquette Medical) First prototype June of 2010; testing last half of 2010;test in surgery 2010-11; FDA trials in 2011-12 Need: Partners (manufacturers, marketers); CEO or board member

Contact Information : 

Contact Information Dr. William Gregory wdguwm@aol.com 5 William Gregory, PhD PE Board Chair & CSO 414 839 3279 wdguwm@aol.com Jack McClurkin, Business Manager William Gregory, CSO & Board Chair